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The fluoroquinolone antimicrobial drug danofloxacin was administered to sheep intravenously (i.v.) and
intramuscularly (i.m.) at a dose of 1.25 mg/kg of body weight in a two-period crossover study. The pharma-
cokinetic properties of danofloxacin in serum, inflamed tissue cage fluid (exudate), and noninflamed tissue
cage fluid (transudate) were established by using a tissue cage model. The in vitro and ex vivo activities of
danofloxacin in serum, exudate, and transudate against a pathogenic strain of Mannheimia haemolytica were
established. Integration of in vivo pharmacokinetic data with the in vitro MIC provided mean values for the
area under the curve (AUC)/MIC for serum, exudate, and transudate of 60.5, 85.6, and 45.7 h, respectively,
after i.v. dosing and 55.9, 77.9, and 49.1 h, respectively, after i.m. dosing. After i.m. dosing, the maximum
concentration/MIC ratios for serum, exudate, and transudate were 10.8, 3.0, and 1.6, respectively. The ex vivo
growth inhibition data after i.m. dosing were fitted to the inhibitory sigmoid Emax equation to provide the
values of AUC/MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria. The
respective values for serum were 17.8, 20.2, and 28.7 h, and slightly higher values were obtained for transudate
and exudate. It is proposed that use of these data might provide a novel approach to the rational design of
dosage schedules.
Danofloxacin is an antibacterial drug of the fluoroquinolone
group developed for use in veterinary medicine. It achieves
high concentrations in several tissues, including the lung (11,
22, 23, 33). Moreover, studies in our laboratory have demon-
strated that the volume of distribution exceeds 3 liters/kg in
four ruminant species after intravenous (i.v.) dosing (28).
However, only one previous publication has described the
pharmacokinetics (PK) of danofloxacin in sheep (22).
The spectrum of antimicrobial activity of danofloxacin is
wide and includes most gram-negative bacteria and some
gram-positive bacteria, mycoplasmas, and intracellular patho-
gens, such as Brucella and Chlamydia species; but it has poor
activity against anaerobes (1, 13, 25, 32). Detailed studies of its
spectrum of activity against sheep pathogens have not been
described, but MICs at which 90% of strains are inhibited
(MIC90s) of #0.25 mg/ml for the cattle pathogens Mannheimia
haemolytica, Pasteurella multocida, Haemophilus somnus, My-
coplasma bovis, and Mycoplasma dispar have been reported (3,
10, 12, 21).
Bacterial diseases in sheep cause morbidity, mortality, suf-
fering, and significant economic losses. Antibacterial drugs are
therefore used in both treatment and prevention programs.
However, there are only limited data on the pharmacology of
antibacterial drugs in sheep. Such data are required for the
design of rational dosage schedules for clinical use. In addition,
the sheep is a suitable species for use in models of disease and
inflammation because of its size, temperament, and the ease of
repeated samplings of blood and other body fluids.
The design of effective dosage schedules is dependent on (i)
the linkage of PK data to ex vivo or in vivo pharmacodynamic
(PD) data generated in animal models or in clinical trials and
(ii) the fact that fluoroquinolones such as danofloxacin act by
a concentration-dependent killing mechanism. A successful
treatment outcome is therefore related to the integrated
PK-PD parameters maximum concentration of drug (Cmax)/
MIC and the area and the curve (AUC)/MIC (2, 5, 6, 7, 8, 14,
15, 16, 19, 20, 26, 27, 31).
The aims of this study were (i) to establish PK data for
danofloxacin in sheep after i.v. and intramuscular (i.m.) dosing;
(ii) to characterize the rate and extent of danofloxacin pene-
tration into inflamed and noninflamed tissues by determining
the distribution into carrageenan-inflamed tissue cage fluid
(exudate) and noninflamed tissue cage fluid (transudate); (iii)
to determine integrated PK-PD parameters (time greater than
the MIC [T . MIC], Cmax/MIC, and AUC/MIC) for dano-
floxacin in vivo; and (iv) to establish, by using the inhibitory
sigmoid Emax equation, the AUC/MICs ex vivo that produce
bacteriostasis, bactericidal action, and elimination of bacteria.
It is proposed that these parameters be used to provide a
rational basis for designing dosage schedules, which will pro-
vide maximal efficacy and minimal opportunity for the emer-
gence of resistant microorganisms (17, 18, 30).
MATERIALS AND METHODS
Animals and experimental design. A two-period crossover study was under-
taken with six healthy sheep (Dorset cross; age, approximately 1 year; mean
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weight, 52.2 6 3.6 kg). Each sheep received danofloxacin (Advocin injectable
solution; Pfizer Animal Health, Sandwich, United Kingdom) at a dose of 1.25
mg/kg of body weight by i.v. and i.m. injection. To maintain social contact, each
sheep was housed in an individual pen and separated from the other sheep by
wire-mesh barriers. Hay and water were provided ad libitum.
In period 1, three sheep received at zero time danofloxacin i.v. in the right
jugular vein and three sheep received the drug in the thigh muscle. In period 2,
treatments were reversed, so that each animal received danofloxacin by both
routes. An interval of 14 days was allowed between each period.
To investigate the penetration of danofloxacin into tissue fluids, the danofloxa-
cin concentrations in carrageenan-inflamed tissue cage fluid (exudate) and non-
inflamed tissue cage fluid (transudate) were determined (see below). The ex vivo
antibacterial activities of danofloxacin in serum, exudate, and transudate against
M. haemolytica (one of the major causative organisms of sheep pneumonia) were
studied. In addition, the in vitro danofloxacin MICs for M. haemolytica in serum,
exudate, and transudate were determined.
Insertion of tissue cages and sampling procedures. Four tissue cages, two on
each side of the neck approximately equidistant from the jugular vein and spinal
cord, were inserted surgically in each animal while the animal was under general
anesthesia. The tissue cages comprised hollow polypropylene balls (internal
diameter, 27 mm; external diameter, 29 mm; internal volume, 10.5 ml; each ball
also had 10 equidistant holes each of 4.8 mm in diameter). The animals were
allowed to recover from surgery for 5 to 6 weeks to permit wound healing and the
growth of granulation tissue into the cages.
To generate exudate, 0.5 ml of a 1% sterile lambda carrageenan solution (Marine
Colloids, Springfield, N.J.) was injected into one tissue cage in each animal at zero
time. A noninjected cage was used to collect transudate. In period 2, the tissue cages
not used in period 1 were used to collect exudate and transudate.
FIG. 1. (a) Semilogarithmic plots of the concentrations of danofloxacin in serum (F), exudate (■ ), and transudate (Œ) after i.v. (a) and i.m.
(b) administration at a dose of 1.25 mg/kg. Values are means 6 SDs (n 5 6).
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Blood samples (5 ml) for determination of the danofloxacin concentration in
serum were collected without anticoagulant in monovettes (Sarstedt, Leicester,
United Kingdom) prior to danofloxacin administration and at 0.083, 0.167, 0.25,
0.33, 0.50, 0.67, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 30, 36, and 48 h after danofloxacin
administration. Serum samples were protected from light and stored at 220°C
prior to analysis.
Transudate and exudate were collected in disposable syringes (1.0 ml of each
fluid) at 1, 3, 6, 9, 12, 24, 30, 36, and 48 h after drug administration and were
protected from light. To remove cells, the samples were centrifuged at 2,000 3
g and 4°C for 10 min. The supernatant was divided into two aliquots, each of
which was stored at 220°C, prior to determination of the danofloxacin concen-
tration and ex vivo antibacterial activity.
Determination of MIC and MBC for M. haemolytica. M. haemolytica W629 (an
United Kingdom sheep isolate of stereotype A1) was grown freshly from beads,
previously stored at 270°C, on tryptone soy blood agar (TSA; Oxoid, Basing-
stoke, United Kingdom). Ten to 12 colonies were used to inoculate 30 ml of
Mueller-Hinton broth (MHB), followed by incubation at 35°C on a shaking
incubator (220 rpm) for 3 h (final concentration, ;108 CFU/ml). Danofloxacin
solution (0.5 ml; made up in each fluid) at twice the required final maximum
concentration was added to 0.25 ml of MHB, serum, exudate, or transudate.
Doubling dilutions from this solution were prepared in each fluid. The percent-
age of water in each final dilution ranged from 0.01 to 0.16%. The following
overlapping sets of doubling dilutions were used to improve the accuracy of the
MIC determinations: 0.015 to 0.240, 0.020 to 0.320, 0.0225 to 0.360, 0.025 to
0.400, and 0.0275 to 0.440 mg/ml. The concentrations used to determine the
MICs were therefore 0.015, 0.020, 0.0225, 0.025, 0.0275 . . . 0.240, 0.320, 0.360,
0.400, and 0.440 mg/ml. Dilutions were prepared in sterile Macrowell tube strips
(Skatron, Newmarket, United Kingdom).
Tubes were inoculated with 0.25 ml of culture to give a final concentration of
approximately 5 3 105 CFU/ml. Inocula were prepared in each fluid at 106
CFU/ml. After the danofloxacin-inoculum mixture was mixed with 0.25 ml of
fluid in each tube, the mixture was diluted with 0.5 ml of MHB in 9 ml of saline
to give a count of 107 CFU/ml. Further 0.5-ml volumes were diluted in 4.5 ml of
each fluid to give a count of 106 CFU/ml. Tubes were incubated at 35°C for 18 h
and then shaken to mix the contents.
An aliquot of 100 ml from each tube was placed in 0.9 ml of saline (1/10
dilution, 1021). Of this, 0.5-ml volumes were serially diluted in 4.5 ml to give
dilutions of 1022, 1023, 1024, and 1025. Controls were further diluted to 1026.
Five 20-ml volumes of each dilution were dropped onto TSA, and the plates were
incubated at 35°C overnight prior to counting of the colonies. The limit of
detection was 10 CFU/ml. MICs were considered the lowest concentration at
which bacterial numbers remained below the original inoculum level, and the
minimum bactericidal concentration (MBC) was the concentration that pro-
duced a 99.9% reduction in the bacterial count.
Ex vivo antimicrobial activity of danofloxacin. M. haemolytica W629 (a United
Kingdom sheep isolate of serotype A1) was grown freshly from beads that had
previously been stored on TSA at 270°C. Eight to 10 colonies were used to
inoculate 9 ml of MHB, and the colonies were allowed to grow overnight at 35°C.
Serum, exudate, and transudate samples from sheep which had received dano-
floxacin i.m. were collected at 0, 1, 3, 6, 9, 12, 24, 30, 36, and 48 h. A total of 10
ml of stationary-phase bacterial culture was added to 1 ml of serum to give a final
concentration of approximately 3 3 107 CFU/ml. Five microliters of stationary-
phase culture was added to 0.35 ml of tissue cage fluids to give a final concen-
tration of approximately 3 3 105 CFU/ml. To determine viable counts, 100 ml of
serum was added to 9.9 ml of saline (dilution, 1022). A total of 100 ml of this
mixture was further diluted in 9.9 ml of saline (total dilution, 1024). For tissue
cage fluids, 50 ml was added to 4.95 ml of saline (dilution, 1022). A total of 50 ml
of this mixture was diluted in 4.95 ml (total dilution, 1024). Controls were further
diluted to 1026. At 3, 6, and 24 h, samples were plated out undiluted as well as
at dilutions of 1022 and 1024. Five 20-ml drops of each dilution were dropped
onto TSA plates. The plates were incubated at 35°C for at least 16 h. The results
were expressed as counts per milliliter. The limit of detection was 10 CFU/ml.
HPLC analysis of danofloxacin in serum and tissue cage fluids. Danofloxacin
concentrations in serum, exudate, and transudate were measured by a high-
pressure liquid chromatography (HPLC) method with fluorescence detection,
modified from the method of Friis (9). Briefly, 0.3 ml of acetonitrile containing
an internal standard at a concentration of 1 mg/ml was added to 0.2 ml of sample.
The contents of the tube were mixed and then centrifuged at 2003 g and 4°C for
10 min. A volume of 0.15 ml of supernatant was diluted with 0.3 ml of HPLC-
grade water, and a 50-ml aliquot was injected onto an HPLC system comprising
a 600E solvent delivery system (Millipore Waters Ltd., Watford, United King-
dom), a 474 fluorescence detector (Millipore Waters), and an SCL 6A/SIL6A
autoinjector and controller (Shimadzu, Milton Keynes, United Kingdom). The
chromatograph consisted of a 15-cm, 5-mm Novapak C18 column (Millipore
Waters) equipped with a Novapak C18 guard column (Millipore Waters). The
mobile phase was 7% acetonitrile–93% buffer (pH 3.0; 0.01 M phosphate buffer
containing 0.008 M tetrabutylammonium sulfate and 0.005 M dibutylamine). The
flow rate was 1.0 ml/min. The excitation and emission wavelengths were 280 and
440 nm, respectively, and the limit of quantitation was 0.005 mg/ml. All chemicals
were supplied by Fisons Ltd. (Loughborough, United Kingdom). The limit of
quantification was 0.005 mg/ml. Within the concentration range of 1 to 10 mg/ml,
the accuracy (percent coefficient of variation) was 240 to 120 and the precision
was less than 30%.
PK analysis. PK parameters for danofloxacin concentration-time data for
serum, exudate, and transudate were calculated by using the PCNONLIN pro-
gram (SCI software; Statistical Consultants Inc., Lexington, Ky.). Minimum
TABLE 1. PK parameters for danofloxacin in serum
after i.v. administrationa
Pharmacokinetic parameterb Mean SD
A (mg/ml) 0.80 0.23
B (mg/ml) 0.30 0.04
a (h21) 2.50 0.94
b (h21) 0.21 0.04
t1/2a (h) 0.37 0.29
t1/2b (h) 3.39 0.75
MRT (h) 3.97 0.56
k10 (/h) 0.62 0.16
k12 (/h) 1.24 0.57
k21 (/h) 0.86 0.33
k12:k21 1.40 0.48
AUC (mg z h/ml) 1.81 0.33
AUMC (mg z h2/ml) 7.35 2.48
Cpo (mg/ml) 1.09 0.25
CL (liter/kg/h) 0.71 0.13
Vc (liter/kg) 1.20 0.27
V (liter/kg) 3.37 0.23
Vss (liter/kg) 2.76 0.17
a The values are means and SDs for six sheep.
b A and B, Y-axis intercept terms; a, distribution rate constant; b, elimination
rate constant; t1/2a, distribution half-life; t1/2b, elimination half-life; MRT, mean
residence time; k10, central compartment elimination rate constant; k12, rate
constant from central to peripheral compartment; k21, rate constant from pe-
ripheral to central compartment; AUC, area under the concentration-versus-
time curve; AUMC, area under the first-moment curve; Cpo, drug concentration
at zero time; CL, body clearance; Vc, volume of distribution in the central
compartment; V, volume of distribution; Vss, volume of distribution at steady
state.
TABLE 2. PK parameters for danofloxacin in exudate and transudate after i.v. administrationa
Fluid kpen (h21) t1/2 pen (h) kel (h21) t1/2b (h)
AUC
(mg z h/ml) Tmax (h) Cmax (mg/ml)
Exudate 2.50 6 2.14 0.46 6 0.25 0.06 6 0.05 17.606 11.67 2.57 6 1.30 2.19 6 1.11 0.1006 0.020
Transudate 0.516 0.21b 1.96 6 1.79b 0.08 6 0.04 10.456 4.88 1.60 6 0.67 5.18 6 2.56b 0.079 6 0.030
a The values are means 6 SDs (n 5 6). kpen, rate constant from central compartment to tissue fluid; t1/2 pen, penetration half-life; kel, tissue fluid elimination rate
constant; t1/2b, tissue fluid elimination half-life; Tmax, time to Cmax; Cmax, maximum drug concentration.
b P , 0.05 for comparison of exudate and transudate.
628 ALIABADI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on August 23, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Akaike Information Criterion Estimates (MAICE) were applied to discriminate
the model with the best fit: MAICE 5 AIC 1 2 P.P., where AIC is the Akaike
Information Criterion and P.P. is the number of primary parameters.
PD analysis. By using in vitro MIC data and in vivo PK parameters, the
surrogate markers of antimicrobial activity, Cmax/MIC, AUC/MIC, and T .
MIC, were determined for serum, exudate, and transudate after both i.v. and i.m.
dosing of danofloxacin.
The relationship between the ex vivo AUC at 24 h (AUC24)/MIC ratio and the
log10 difference between the initial bacterial count (in number of CFU per
milliliter) and the bacterial count after 24 h of incubation was established for
serum, exudate, and transudate by using the sigmoid inhibitory Emax model. This
model is described by the following equation: E 5 E0 1 [(Emax z CeN)/(EC50N 1
Ce
N)], where E is the antibacterial effect measured as the change in the bacterial
count (in log10 CFU per milliliter) in the serum, exudate, or transudate sample
after 24 h of incubation compared to the initial log10 CFU per milliliter; Emax is
the log10 difference in bacterial count between 0 and 24 h in the control sample;
E0 is the log10 difference in bacterial count in the test sample containing dano-
floxacin after 24 h of incubation when the limit of detection of 10 CFU/ml is
reached; EC50 is the AUC24/MIC producing 50% of the maximal antibacterial
effect; Ce is the AUC24/MIC in the effect compartment (the ex vivo site, that is,
serum, exudate, or transudate); and N is the Hill coefficient, which describes the
steepness of the (AUC24/MIC)-effect curve. In this investigation, because the
drug is inhibitory to bacterial growth, Emax represents the baseline bacterial
count and E0 is the maximal effect. This is in contrast to the usual convention that
E0 is the baseline value and Emax represents the maximum change from the
baseline value. These PD parameters were calculated by using the WINNONLIN
nonlinear regression program (SCI software).
Four levels of antibacterial effect of danofloxacin were quantified from the
sigmoid Emax equation by determining AUC24/MICs required for bacteriostatic
action (no change in bacterial count after 24 h of incubation), a 50% reduction
in the bacterial count, bactericidal action (a 99.9% decrease in the bacterial
count), and bacterial elimination (the lowest AUC24/MIC that produced a re-
duction in the count to 10 CFU/ml) in each of the fluids (serum, exudate, and
transudate).
The AUC24/MICs required for bacteriostatic and bactericidal activities were
determined by using a model written in the laboratory of the Department of
Veterinary Basic Sciences, The Royal Veterinary College, by using the WIN-
NONLIN program, while elimination values were obtained from the (AUC24/
MIC)-effect curve when the lines for the observed and the predicted values were
matched.
Statistical analyses. Statistical analyses were undertaken by analysis of vari-
ance, and significant differences, when they occurred, were examined by using
Bonferroni’s correction for intergroup comparisons. Differences were accepted
as significant for P values ,0.05.
RESULTS
Danofloxacin MICs and MBCs. The MICs and MBCs of
danofloxacin in MHB and undiluted serum, exudate, and tran-
sudate were determined. The MICs were 0.03 mg/ml in broth,
serum, and exudate and 0.035 mg/ml in transudate. The MBCs
were 0.040 mg/ml in serum and 0.045 mg/ml in broth, exudate,
and transudate.
i.v. administration of danofloxacin. (i) Danofloxacin concen-
trations in serum, exudate, and transudate. The mean 6 stan-
dard deviation (SD) concentrations of danofloxacin in serum,
exudate, and transudate are presented in Fig. 1a. The data for
serum were best fitted to a two-compartmental model for all six
sheep (Table 1).
Danofloxacin penetration into carrageenan-inflamed tissue
cage fluid was more rapid than that into transudate. Mean
penetration half-lives (t1/2 pens) were 0.46 and 1.96 h, respec-
tively (P , 0.05) (Table 2). By 6 h and subsequently up to the
last sampling time (48 h), the danofloxacin concentrations in
both exudate and transudate were higher than the concentra-
tions in serum (Fig. 1a). The mean Cmax of 0.100 mg/ml in
exudate was achieved at 2.19 h. The corresponding data for
transudate were 0.079 mg/ml at a later time of 5.18 h (P , 0.05
for the time to Cmax) (Table 2). The elimination half-lives
(t1/2bs) in both tissue cage fluids (17.6 h for exudate [P , 0.05]
and 10.5 h for transudate [P, 0.05]) were longer than those in
serum.
(ii) PK-PD integration for danofloxacin in serum, exudate,
and transudate. The PK-PD integration parameters for the in
vivo PK data and the MICs measured in vitro for serum,
exudate, and transudate are presented in Table 3. i.v. admin-
istration of danofloxacin (1.25 mg/kg) provided an AUC/MIC
of 60.5 h for M. haemolytica W629 in serum. The time for
which the concentration in serum exceeded the MIC was
10.9 h. Hence, the concentration of drug in serum remained
above the MIC for almost half of the recommended dosage
interval of 24 h.
The AUC/MIC was 85.6 h for M. haemolytica W629 in ex-
udate. The corresponding value in transudate was 45.7 h, but
this value was not significantly different from that obtained in
exudate. The Cmax/MIC was 3.35 for exudate. A lower value of
2.25 was obtained for transudate (P , 0.05).
The T.MIC for danofloxacin in exudate was 27.2 h. There-
TABLE 3. In vivo PK-PD integration parameters for danofloxacin
after i.v. and i.m. administration at a dose of 1.25 mg/kga
Route of
administration
and fluid
AUC/MIC
(h) Cmax/MIC
T . MIC
(h)
i.v.
Serum 60.5 6 11.1 NAb 10.9 6 2.1
Exudate 85.6 6 43.2 3.35 6 0.81 27.2 6 17.7
Transudate 45.7 6 19.2 2.25 6 0.86c 16.3 6 7.3
i.m.
Serum 55.9 6 39.4 10.79 6 0.86 12.1 6 2.5
Exudate 77.9 6 19.8 3.03 6 1.13d 27.0 6 8.1d
Transudate 49.1 6 17.1c 1.57 6 0.44c,d 16.6 6 5.3c
a The values are means 6 SDs (n 5 6).
b NA, not applicable.
c P , 0.05 for comparison of exudate and transudate.
d P , 0.01 for comparison of serum and exudate or transudate.
TABLE 4. PK parameters for danofloxacin after i.m. administrationa
Fluid kabs (h21) t1/2a (h) tlag (h) kel (h21) t1/2b (h) AUC (mg z h/ml) Tmax (h) Cmax (mg/ml) F (%)
Serum 6.17 6 4.53 0.17 6 0.10 NA 0.226 0.01 3.17 6 0.17 1.68 6 0.27 0.706 0.37 0.324 6 0.024 98.56 17.4
Exudate 1.05 6 1.00 1.13 6 0.64 0.64b 0.06 6 0.05 17.13 6 9.53 2.34 6 0.59 4.466 0.20 0.091 6 0.023 NA
Transudate 0.566 0.59 2.00 6 1.00 0.58 6 0.17 0.05 6 0.02 17.66 6 8.06 1.72 6 0.59 6.966 3.04 0.055 6 0.025c NA
a The values are means 6 SDs (n 5 6 unless indicated otherwise).
b n 5 1. kabs, absorption rate constant for serum and penetration rate constant for exudate and transudate; t1/2a, absorption half-life for serum and penetration
half-life for exudate and transudate; tlag, lag time; F, bioavailability; NA, not applicable. See footnote a of Table 2 for the definitions of the other variables.
c P , 0.05 for comparison of exudate and transudate.
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fore, the concentrations in exudate remain above the MIC
longer than the recommended dosage interval (24 h), although
the AUC/MIC of 85.6 h is below what might be the optimal
level. The T . MIC for danofloxacin in transudate was not
significantly different from the T . MIC in exudate.
i.m. administration of danofloxacin. (i) Danofloxacin con-
centrations in serum, exudate, and transudate. The mean 6
SD serum danofloxacin concentrations after i.m. administra-
tion at a dose of 1.25 mg/kg are presented in Fig. 1b. Data for
serum were best fitted to a monocompartmental model for all
animals except one (sheep 4), for which the danofloxacin con-
centrations were best described by a two-compartmental
FIG. 2. Ex vivo antibacterial activity of danofloxacin (plots of log10 CFU per milliliter versus time) against M. haemolytica W629 in serum (a),
exudate (b), and transudate (c) after i.m. administration at a dose of 1.25 mg/kg. Values are means (n 5 6). SD bars are excluded for clarity.
Samples were harvested at predetermined times between 0 and 48 h. Data for samples collected at 30 and 36 h are not shown. Cont., control serum
containing no danofloxacin.
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model. Absorption was rapid after i.m. dosing; the mean ab-
sorption half-life (t1/2a) was 0.17 h (Table 4). The mean dano-
floxacin Cmax of 0.324 mg/ml was achieved in 0.70 h. Dano-
floxacin bioavailability was complete (98.5%). The t1/2b was
3.17 h, and this value was similar to that achieved after i.v.
dosing.
Danofloxacin penetration into both exudate and transudate
was fairly rapid (Table 4). The Cmaxs in these fluids were 0.091
mg/ml (at 4.46 h) and 0.055 mg/ml (at 6.96 h), respectively.
Cmaxs were significantly different (P , 0.05) for exudate and
transudate, while the time to Cmax was not significantly differ-
ent for exudate and transudate. t1/2bs were almost six times
longer for both nonvascular fluids than for serum (17.13 and
17.66 h for exudate and transudate, respectively). The AUC for
danofloxacin in exudate was higher than that in serum (2.34
and 1.68 mg · h/ml, respectively), but the difference was not
significant. The mean AUC (1.72 mg · h/ml) in transudate was
similar to that in serum. The danofloxacin concentrations in
tissue cage fluids were greater than those in serum by 9 h and
thereafter (Fig. 1b).
(ii) PK-PD integration for danofloxacin in serum, exudate,
and transudate. The PK-PD integration parameters for the in
vivo PK data and the MIC measured in vitro are presented in
Table 3. i.m. administration of danofloxacin at a dose of 1.25
mg/kg produced an in vivo AUC/MIC for M. haemolytica W629
in serum of 55.9 h. The mean T . MIC was 12.1 h, while the
Cmax/MIC was 10.8. Therefore, treatment with danofloxacin at
a dose of 1.25 mg/kg in sheep would be expected to be very
effective against this strain of M. haemolytica.
The T . MIC was 27.0 h in exudate. The mean Cmax/MIC
ratio was 3.03, and the mean AUC/MIC was 77.9 h. The AUC/
MIC for M. haemolytica W629 in transudate was 49.1 h, which
was less than the value in exudate (P , 0.05). The mean
Cmax/MIC in transudate (1.57) was also less than that in exu-
date (P , 0.05). The mean T . MIC in transudate of 16.6 h
was less than that in exudate (P , 0.05).
(iii) Danofloxacin ex vivo antibacterial activity in serum,
exudate, and transudate. The ex vivo activity of danofloxacin
against M. haemolytica W629 in serum was determined at nine
time points by using samples harvested between 1 and 48 h.
For all samples collected from all animals in the first 9 h,
danofloxacin exerted a very good bactericidal effect after only
6 h of incubation (Fig. 2a). After 24 h of incubation almost all
bacteria were killed (detection limit, 10 CFU/ml) for all sam-
ples collected between 1 and 9 h. For samples collected at 12 h,
good bactericidal activity was obtained for samples from two
animals after 24 h of incubation. There was inhibition of
growth for samples from two additional sheep, and there was
no inhibition of bacterial growth for the samples from the two
remaining sheep. No bacteriostatic or bactericidal effects were
obtained for serum samples collected at 24, 30, 36, and 48 h.
Exudate samples collected at nine time points between 1 and
48 h were selected for study. For all samples collected between
3 and 12 h, danofloxacin exerted a good bactericidal effect after
6 h of incubation, while after 24 h of incubation, all or almost
all bacteria were killed (Fig. 2b). No inhibitory effects on bac-
terial growth were obtained for samples collected at 30, 36, and
48 h. The arithmetic mean bacterial count was high for exudate
samples collected at 1 h, indicating no apparent bactericidal
effect. However, a good bactericidal effect was obtained for
samples from three of four animals.
Transudate samples collected at nine time points between 1
and 48 h were selected for study. For samples selected at 3 h
the arithmetic mean bacterial count remained high, indicating
no apparent inhibitory effect of danofloxacin (Fig. 2c). How-
ever, good bactericidal activity was obtained for samples from
FIG. 2—Continued.
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two of five animals. Similarly, whenever the drug concentration
was sufficiently high, there was a good bactericidal effect for
samples collected at 6 h. Bactericidal activity was also exhibited
for samples collected at 9 and 12 h. Neither bacteriostatic
activity nor bactericidal activity was obtained for samples col-
lected at 1, 30, 36, and 48 h.
(iv) In vivo and ex vivo AUC24/MIC of danofloxacin for M.
haemolytica W629. The in vivo and ex vivo AUC24/MIC ratios
for danofloxacin in sheep fluids after i.m. administration of the
drug at a dose of 1.25 mg/kg are presented in Table 5. An ex
vivo AUC24/MIC of 35 h for serum samples collected at 9 h
provided a good bactericidal effect, sufficient to eliminate bac-
teria almost completely after 24 h of incubation (Fig. 2a; Table
5). To provide rapid elimination within 3 h of incubation, an
AUC24/MIC equal to or greater than 16 h was required (for
samples collected at 1 and 3 h). Danofloxacin administration
provided a mean in vivo AUC24/MIC of 56 h for the serum
samples. This was approximately 1.5 times greater than the ex
vivo AUC24/MIC for serum samples collected at 9 h, which
almost completely eliminated the bacteria after 24 h of incu-
bation.
An ex vivo AUC24/MIC of 17 h was obtained for exudate
samples collected at 30 h, and this did not affect bacterial
growth (Fig. 2b; Table 5). However, an AUC24/MIC of 43 h for
samples collected at 12 h was sufficient to eliminate the bac-
teria after incubation for 24 h (Fig. 2b). Danofloxacin admin-
istration produced an in vivo AUC24/MIC of 46 h for exudate
samples, which is almost identical to the ex vivo AUC24/MIC
for the samples collected at 12 h, which eliminated the bacte-
ria.
An ex vivo AUC24/MIC of 30 h for transudate samples
collected at 12 h was sufficient to eliminate the bacteria (Fig.
2c; Table 5). i.m. administration of danofloxacin provided an in
vivo AUC24/MIC of 28 h, which is similar to the ex vivo values
of 12 h that produced bacterial elimination. The concentra-
tions of danofloxacin achieved in vivo in serum, exudate, and
transudate should therefore be effective in curing infection
with M. haemolytica W629 under clinical circumstances. Sta-
tistically significant differences between the three fluids are
indicated in Table 5.
(v) Ex vivo AUC24/MIC required for bacteriostasis, bacteri-
cidal activity, and elimination of bacteria. The ex vivo compo-
nent of the study yielded AUC24/MICs for serum, exudate, and
transudate and also provided bacterial growth inhibition curves
over the 24-h incubation period. These two data sets were
integrated by using the inhibitory form of the sigmoid Emax
equation to provide numerical values of AUC24/MIC required
for various degrees of bacterial inhibition. Graphs depicting
the bacterial count and AUC24/MIC relationships for serum,
exudate, and transudate are presented in Fig. 3a, b, and c,
respectively. The calculated mean AUC24/MICs for serum that
produced bacteriostasis (no change in the number of bacteria),
bactericidal activity (a 3-log reduction in the bacterial count),
and elimination of bacteria (a reduction in the bacterial count
to ,10 CFU/ml) were 17.79, 20.18, and 28.67 h, respectively
(Table 6). Slightly higher values for each integrated variable
were obtained for exudate and transudate (Table 6), but the
only statistically significant difference was the higher AUC24/
MIC for exudate required to eliminate bacteria in comparison
with the corresponding value for serum (P, 0.05). The finding
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that the danofloxacin AUC24/MICs that produced bactericidal
activity in all three fluids were only slightly greater than those
that produced bacteriostasis is explained by the steep slope
of the AUC24/MIC-versus-bacterial count relationship (Table
6).
DISCUSSION
The i.v. and i.m. administration of danofloxacin at a dose of
1.25 mg/kg to sheep yielded values for PK variables which
were, in most instances, similar to those obtained by McKellar
et al. (22). The present study extends the findings of McKellar
FIG. 3. Plots of ex vivo AUC24/MIC versus bacterial count (log10 CFU per milliliter) for M. haemolytica W629 in serum (a), exudate (b), and
transudate (c). The points represent the values observed for individual animals, and the curve is the line of best fit, based on the sigmoid Emax
equation.
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et al. (22), however, by demonstrating the relatively rapid pen-
etration into the inflammatory exudate during acute inflamma-
tion and the slow elimination of danofloxacin from the inflam-
matory exudate during acute inflammation. The penetration of
drugs into tissue cage fluids is dependent in part on the dimen-
sions and shapes of the cages and in part on the age and extent
of granulation tissue growth into the cages and the vascularity
of that growth. In addition, in the present study, the acute
inflammation of the tissue within the cage facilitated dano-
floxacin penetration. This is illustrated by the somewhat slower
penetration into transudate fluids of noninflammed tissue
cages. These findings may be relevant to danofloxacin pene-
tration to sites of infection, although it should be noted that
the inflammation in the present study was sterile.
Determinations of antimicrobial drug efficacy and potency
have been undertaken in innumerable in vitro, ex vivo, and in
vivo studies. Each approach is associated with a number of
advantages and disadvantages. Thus, the most commonly used
measure of in vitro potency is the MIC. Although it is simple
to determine the MIC, the MIC is a relatively crude index since
it is usually measured by a doubling dilution procedure. More-
over, use of an artificial medium such as broth to measure the
MIC does not closely simulate in vivo conditions. Therefore, in
this study MICs were determined in undiluted serum, exudate,
and transudate to enable meaningful calculation of the derived
variables such as AUC/MIC for each fluid. In addition, to
improve accuracy, MICs were determined by using five over-
lapping sets of doubling dilutions.
Doses of antimicrobial agents for clinical use are generally
determined by relating the PK data obtained for healthy ani-
mals either to some measure of in vitro antibacterial activity,
usually the MIC, or to the outcome of treatment in a disease
model or clinical subjects. To address the limitations of com-
monly used methods, this study has attempted to relate drug
PDs to drug PKs in a novel way in an ex vivo model. The ex
vivo AUC24/MIC data were integrated by using the sigmoid
Emax equation with the reduction in bacterial numbers after
24 h of incubation. From these measurements, the lowest ef-
fective ex vivo AUC24/MICs required for bacteriostasis, bacte-
ricidal activity, and total killing of the bacteria were deter-
mined for each of the fluids evaluated, serum, exudate, and
transudate. For serum the values were 17.8, 20.2, and 28.7 h,
respectively, and slightly higher values were obtained for exu-
date and transudate.
By using the lowest ex vivo AUC24/MIC required to elimi-
nate all organisms after 24 h of incubation, calculation of the
optimal dosage has been undertaken by the equation x 5 [1.25
3 (targeted AUC24/MIC ex vivo)]/[(AUC/MIC in vivo) for a
dose of 1.25 mg/kg)], where x is the projected dosage. The
values of x obtained for serum, exudate, and transudate were
0.641, 0.667, and 0.847 mg/kg, respectively. Assuming an
MIC90 of 0.25 mg/ml, the corresponding dosages would be 5.34,
5.56, and 6.05 mg/kg. The similarity of these values for the
three types of biological fluid supports use of the data obtained
by this method to set provisional dosage schedules. However,
because of possible in vivo and ex vivo differences in antimi-
crobial activity, the dosage obtained by this method might not
be recommended for clinical use but might be recommended
for evaluation in clinical trials. This recommended dosage
would be modified if the MIC90 differed from the assumed
value of 0.25 mg/ml.
It might be argued that optimization of dosage schedules by
use of the principles outlined in this paper will involve the
administration of amounts of drug in excess of those required
to achieve clinical and bacteriological cures in the majority of
animals. This may be so; indeed, it is inevitable. Nevertheless,
this approach should ensure not only optimal efficacy but also
minimal opportunity for the emergence of resistant organisms,
a very significant consideration at present.
Previous studies have shown that for plasma fluoroquino-
lone Cmax/MICs greater than 3 produce 99% reductions in
bacterial counts and that Cmax/MICs of 8 or greater suffice to
prevent the emergence of resistant bacteria when the MICs for
the subpopulation are four- to eightfold higher (2). Dudley (7)
confirmed that selection of resistant bacteria may occur with a
fluoroquinolone dosage regimen which produced a Cmax/MIC
less than 8. A similar Cmax/MIC (greater than 8) for amino-
glycosides was likewise required to prevent regrowth of the
resistant subpopulation of bacteria, for which MICs were four-
to eightfold higher (2, 4, 16). Other investigations have con-
firmed that for aminoglycosides optimal bactericidal activity
was achieved with a Cmax/MIC ratio of 8 to 10 (24, 26). The
mechanism underlying the association of Cmax/MIC and both
treatment efficacy and reduction of the emergence of resis-
tance is not certain. It might be explained by both the postan-
tibiotic effect and the postantibiotic sub-MIC effect phenom-
ena.
In summary, the PK-PD integration methods described in
this paper may provide the basis for the design of a dosing
schedule that will ensure bacteriological cure and minimize
resistance development. The approach might be used to assist
with the selection of a dosage for subsequent evaluation in
clinical trials. The methods might also be used as a means of
providing guidelines for registration bodies which are required
TABLE 6. PK-PD integration of ex vivo danofloxacin data after i.m. administration at a dose of 1.25 mg/kga
Fluid Log E0(CFU/ml)
Log Emax
(CFU/ml)
Log Emax 2 log E0
(CFU/ml)
AUC24/MIC for
bacteriostati
action (h)
AUC24/MIC
EC50b
AUC24/MIC for
bactericidal
action
AUC24/MIC
for bacterial
elimination
Slope (n)c
Serum 24.967 6 0.149 1.7836 0.678 6.7496 0.607 17.79 6 4.26 19.10 6 4.34 20.186 4.21 28.67 6 4.33 17.046 7.10
Exudate 24.982 6 0.072 1.3926 0.442 6.3746 0.386 20.57 6 2.20 23.38 6 2.34 25.456 2.94 41.60 6 8.72d 14.87 6 10.20
Transudate 25.001 6 0.016 1.226 6 0.094 6.2286 0.082 20.89 6 5.38 22.376 4.90 23.17 6 4.74 33.266 3.08 36.036 22.26
a The values are means 6 SDs (n 5 6 for serum and n 5 4 for exudate and transudate).
b AUC24/MIC EC50, AUC24/MIC of drug producing 50% of the maximum antibacterial effect.
c n 5 slope of the AUC24/MIC-response curve.
d P , 0.05 for comparison of serum and exudate.
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to verify the efficacy claims made by pharmaceutical companies
applying for marketing authorizations for human and veteri-
nary products. However, the present approaches to PK-PD
integration require further development. There is now a need
to design experiments with either naturally diseased animals or
disease models to establish the lowest AUC/MICs that result in
the elimination of bacteria in vivo. Such experiments will fur-
ther provide a rational basis for the selection of optimal dosage
schedules for antimicrobial agents. Finally, we have proposed
that establishment of clinical and bacteriological efficacies in
vivo, which are linked to population PK data, are a necessary
development for establishment of antimicrobial dosage sched-
ules (17, 18, 29, 30).
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